People: Amneal Pharmaceuticals Inc (AMRX.N)

AMRX.N on New York Stock Exchange

30 Sep 2020
Change (% chg)

$0.03 (+0.78%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Buchi, J. Kevin 

Mr. J. Kevin Buchi serves as Independent Director of the Company. Mr. Buchi served as Corporate Vice President, Global Branded Products of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), from October 2011 to May 2012. Prior to Teva, Mr. Buchi served as CEO of Cephalon, Inc. (formerly Nasdaq: CEPH), which was subsequently acquired by Teva, from December 2010 to October 2011, and held various positions at Cephalon, including Chief Operating Officer from January 2010 to December 2010 and Chief Financial Officer from 1996 to 2009. Since April 2013, Mr. Buchi has served as a director and member of the remuneration and nominating committee, and audit committee of the board of Benitec Biopharma Ltd. (Nasdaq: BNTC), a biotechnology company headquartered in Australia. Since August 2018, Mr. Buchi has served as a director and chairman of the board of Dicerna Pharmaceuticals (Nasdaq: DRNA). Mr. Buchi previously served as a director until 2016 of the following companies: Epirus Biopharmaceuticals, Alexza Pharmaceuticals, Stemline Therapeutics, and Forward Pharmaceuticals. Mr. Buchi received his BA degree from Cornell University and a Masters of Management from the J.L. Kellogg Graduate School of Management at Northwestern University. Mr. Buchi’s extensive experience as a senior executive and board member in the pharmaceutical industry provides the Board with unique insights into our business.

Basic Compensation

Total Annual Compensation, USD --
Restricted Stock Award, USD 90,749
Long-Term Incentive Plans, USD --
All Other, USD 299,507
Fiscal Year Total, USD 390,256

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --